MedinCell S.A. (MEDCL.PA) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2026-03-31. MEDCL.PA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.72% | 30.00% | Pass |
| Interest-bearing investments | 9.54% | 30.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 55.34% | 33.00% | Fail |
| Interest-bearing investments | 78.50% | 33.00% | Fail |
| Non-liquid assets | 19.99% | at least 20.00% | Fail |
| Non-permissible income | 0.02% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 55.34% | 33.33% | Fail |
| Cash + interest-bearing securities | 78.50% | 33.33% | Fail |
| Accounts receivable | 80.01% | 33.33% | Fail |
| Non-permissible income | 0.02% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 55.34% | 33.33% | Fail |
| Cash + interest-bearing securities | 78.50% | 33.33% | Fail |
| Accounts receivable | 80.01% | 50.00% | Fail |
| Non-permissible income | 0.02% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.65% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.85% | 33.00% | Pass |
| Accounts receivable | 0.21% | 33.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 9.41% | 33.00% | Pass |
| Cash + interest-bearing securities | 13.35% | 49.00% | Pass |
| Accounts receivable | 0.26% | 49.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 9.41% | 33.33% | Pass |
| Cash + interest-bearing securities | 13.35% | 33.33% | Pass |
| Accounts receivable | 13.61% | 49.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 30.70 | NEUTRAL |
| Stochastic %K (14) | 9.39 | BUY |
| CCI (20) | -170.25 | BUY |
| Williams %R (14) | -90.61 | BUY |
| MACD (12,26,9) | -0.19 | SELL |
| ROC (10) | -10.91 | SELL |
| Momentum (10) | -2.69 | SELL |
| EMA (10) | 22.84 | SELL |
| SMA (10) | 23.03 | SELL |
| EMA (20) | 23.53 | SELL |
| SMA (20) | 23.76 | SELL |
| EMA (30) | 24.00 | SELL |
| SMA (30) | 24.12 | SELL |
| EMA (50) | 24.58 | SELL |
| SMA (50) | 25.12 | SELL |
| EMA (100) | 25.13 | SELL |
| SMA (100) | 25.80 | SELL |
| EMA (200) | 25.70 | SELL |
| SMA (200) | 25.11 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2026-03-31, figures in EUR.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.